SIMILAR PATTERNS OF AMINO ACIDS FOR 5YU9_C_1E8C1101

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 ASP A 539	None	0.89A	5yu9C-1k2pA: 28.4	5yu9C-1k2pA: 14.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	VAL A 209 ALA A 220 GLY A 272 ASP A 276 ASP A 332	None	0.71A	5yu9C-1k9aA: 29.6	5yu9C-1k9aA: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	VAL A 219 ALA A 230 LEU A 278 GLY A 286 ASP A 351	PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.8A) PY1 A 700 (-3.6A) PY1 A 700 (-2.7A)	0.68A	5yu9C-1py5A: 24.3	5yu9C-1py5A: 11.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 219 ALA A 230 LYS A 232 GLY A 286 ASP A 290 ASP A 351	PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.9A) PY1 A 700 (-3.6A) None PY1 A 700 (-2.7A)	1.00A	5yu9C-1py5A: 24.3	5yu9C-1py5A: 11.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 99 LYS A 101 MET A 147 GLY A 153 ASP A 212	ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 3.4A) ATP A 535 ( 4.7A) MG A 536 (-3.3A)	0.74A	5yu9C-1s9iA: 16.0	5yu9C-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 86 ALA A 99 LYS A 101 GLY A 153 ASP A 212	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) ATP A 535 ( 4.7A) MG A 536 (-3.3A)	0.62A	5yu9C-1s9iA: 16.0	5yu9C-1s9iA: 15.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 LEU A 433 GLY A 441 ASP A 445 ASP A 500	None	0.93A	5yu9C-1snxA: 22.6	5yu9C-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 LEU A 433 GLY A 441 CYH A 442 ASP A 445	None	0.83A	5yu9C-1snxA: 22.6	5yu9C-1snxA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2b1p	MITOGEN-ACTIVATED PROTEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 78 ALA A 91 LYS A 93 LEU A 144 MET A 146	AIZ A 501 ( 4.7A) AIZ A 501 (-3.4A) AIZ A 501 (-3.8A) AIZ A 501 (-4.2A) AIZ A 501 (-3.8A)	0.45A	5yu9C-2b1pA: 18.0	5yu9C-2b1pA: 14.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 ASP A 404	H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None H8H A 534 (-3.3A) None H8H A 534 (-4.2A)	0.70A	5yu9C-2h8hA: 32.1	5yu9C-2h8hA: 12.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 ASP A 404	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.0A) QUE A 1 ( 4.1A) None	0.98A	5yu9C-2hckA: 30.2	5yu9C-2hckA: 11.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	VAL A 352 ALA A 367 LYS A 369 MET A 390 LEU A 412 GLY A 420 ASP A 479	ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None None ANP A 615 ( 3.9A) MG A 614 ( 3.2A)	0.76A	5yu9C-2ozoA: 22.7	5yu9C-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 352 ALA A 367 MET A 390 MET A 414 GLY A 420 ASP A 479	ANP A 615 (-4.5A) ANP A 615 (-3.3A) None ANP A 615 ( 3.9A) ANP A 615 ( 3.9A) MG A 614 ( 3.2A)	1.18A	5yu9C-2ozoA: 22.7	5yu9C-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 352 LYS A 369 MET A 390 LEU A 412 GLY A 418 ASP A 479	ANP A 615 (-4.5A) ANP A 615 (-3.1A) None None ANP A 615 ( 4.0A) MG A 614 ( 3.2A)	1.01A	5yu9C-2ozoA: 22.7	5yu9C-2ozoA: 8.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	VAL A 33 ALA A 46 LEU A 101 GLY A 109 ASP A 113 THR A 166	ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None None ATP A 381 ( 4.6A)	0.71A	5yu9C-2phkA: 21.6	5yu9C-2phkA: 17.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 LYS B 69 LEU B 112 GLY B 120 THR B 181	None	0.72A	5yu9C-2qkwB: 21.9	5yu9C-2qkwB: 15.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LEU A 263 GLY A 271 ASP A 275 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 ( 4.1A) None None	0.82A	5yu9C-2qluA: 23.7	5yu9C-2qluA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LYS A 217 LEU A 263 ASP A 275 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None None None None	0.97A	5yu9C-2qluA: 23.7	5yu9C-2qluA: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 749 LYS A 751 LEU A 794 ARG A 847 THR A 860 ASP A 861	GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) None GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	1.35A	5yu9C-2r4bA: 37.2	5yu9C-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LYS A 751 MET A 772 LEU A 794 THR A 860 ASP A 861	GW7 A 1 (-3.9A) GW7 A 1 ( 3.8A) GW7 A 1 (-4.1A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.75A	5yu9C-2r4bA: 37.2	5yu9C-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 732 ALA A 749 LYS A 751 LEU A 794 GLY A 802 THR A 860	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) GW7 A 1 (-3.6A) GW7 A 1 (-3.5A)	0.75A	5yu9C-2r4bA: 37.2	5yu9C-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 732 ALA A 749 LYS A 751 LEU A 794 THR A 860 ASP A 861	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.65A	5yu9C-2r4bA: 37.2	5yu9C-2r4bA: 18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 234 ALA A 247 GLY A 307 ASP A 311 THR A 367	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 ( 3.7A) None XK9 A1511 (-3.7A)	0.48A	5yu9C-2xk9A: 11.7	5yu9C-2xk9A: 14.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 234 ALA A 247 LYS A 249 GLY A 307 ASP A 311	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.2A) XK9 A1511 ( 3.7A) None	0.79A	5yu9C-2xk9A: 11.7	5yu9C-2xk9A: 14.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 ALA A 51 GLY A 113 ASP A 117 ASP A 171	None B49 A1294 (-3.2A) B49 A1294 (-3.6A) None B49 A1294 (-4.2A)	0.70A	5yu9C-2y7jA: 21.9	5yu9C-2y7jA: 13.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 ALA A 51 LEU A 105 GLY A 113 ASP A 117	None B49 A1294 (-3.2A) None B49 A1294 (-3.6A) None	0.49A	5yu9C-2y7jA: 21.9	5yu9C-2y7jA: 13.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 76 ALA A 92 LYS A 94 LEU A 139 THR A 204	None STU A 1 (-3.3A) STU A 1 (-2.8A) None STU A 1 (-3.6A)	0.69A	5yu9C-2z7rA: 21.8	5yu9C-2z7rA: 12.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	5	VAL A 261 ALA A 273 LYS A 275 GLY A 325 ASP A 329	None	0.73A	5yu9C-2zv7A: 25.2	5yu9C-2zv7A: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 209 ALA A 220 GLY A 272 ASP A 276 ASP A 332	None	0.71A	5yu9C-3d7uA: 24.2	5yu9C-3d7uA: 19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 31 ALA A 44 LYS A 46 MET A 67 LEU A 90 ASP A 102 ASP A 164	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) ANP A 1 (-2.8A) None None None ANP A 1 (-3.8A)	0.83A	5yu9C-3dakA: 22.4	5yu9C-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 31 ALA A 44 MET A 67 LEU A 90 GLY A 98 ASP A 164	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None None ANP A 1 (-3.8A)	0.77A	5yu9C-3dakA: 22.4	5yu9C-3dakA: 15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 158 ALA A 169 LEU A 218 GLY A 226 THR A 293	VIN A6331 (-4.7A) VIN A6331 (-3.4A) None VIN A6331 (-3.4A) VIN A6331 (-3.6A)	0.48A	5yu9C-3dtcA: 19.7	5yu9C-3dtcA: 14.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	5	VAL A 37 ALA A 50 LEU A 98 ASP A 110 ASP A 167	None	0.57A	5yu9C-3dxnA: 24.6	5yu9C-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	5	VAL A 37 ALA A 50 LEU A 98 GLY A 106 ASP A 167	None	0.55A	5yu9C-3dxnA: 24.6	5yu9C-3dxnA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	5	ALA A 247 GLY A 307 ASP A 311 THR A 367 ASP A 368	None	0.69A	5yu9C-3i6uA: 22.2	5yu9C-3i6uA: 10.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 704 LYS A 723 LEU A 766 GLY A 774 ASP A 778 ASP A 833	ANP A 1 (-3.9A) ANP A 1 (-3.4A) None ANP A 1 ( 4.9A) None MG A1001 ( 3.1A)	0.70A	5yu9C-3kexA: 30.1	5yu9C-3kexA: 15.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	ALA A 719 LYS A 721 MET A 742 LEU A 764 GLY A 772 CYH A 773 ASP A 776 THR A 830 ASP A 831	ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.4A) ITI A 1 ( 4.2A) ITI A 1 (-3.5A) ITI A 1 (-4.8A) None ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	0.76A	5yu9C-3lzbA: 38.9	5yu9C-3lzbA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 753 GLY A 772 CYH A 773 ASP A 776 THR A 830 ASP A 831	ITI A 1 (-3.8A) ITI A 1 (-3.5A) ITI A 1 (-4.8A) None ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	1.29A	5yu9C-3lzbA: 38.9	5yu9C-3lzbA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 702 ALA A 719 LYS A 721 MET A 742 LEU A 764 CYH A 773 ASP A 776 THR A 830 ASP A 831	ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.4A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A) None ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	0.75A	5yu9C-3lzbA: 38.9	5yu9C-3lzbA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pls	MACROPHAGE-STIMULATI NG PROTEIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A1096 ALA A1112 LYS A1114 GLY A1167 ASP A1226	ANP A1358 (-4.4A) ANP A1358 ( 3.8A) ANP A1358 (-3.2A) None MG A 1 ( 3.2A)	0.65A	5yu9C-3plsA: 30.4	5yu9C-3plsA: 16.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 734 ALA A 751 LEU A 796 GLY A 804 CYH A 805 ASP A 808 ASP A 863	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) 03Q A 1 ( 3.9A) None None 03Q A 1 (-4.0A)	0.85A	5yu9C-3pp0A: 34.8	5yu9C-3pp0A: 59.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 734 ALA A 751 LEU A 796 GLY A 804 CYH A 805 ASP A 808 THR A 862	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) 03Q A 1 ( 3.9A) None None 03Q A 1 (-3.3A)	0.62A	5yu9C-3pp0A: 34.8	5yu9C-3pp0A: 59.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 734 ALA A 751 LYS A 753 LEU A 796 CYH A 805 ASP A 863	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.3A) None 03Q A 1 (-4.0A)	1.11A	5yu9C-3pp0A: 34.8	5yu9C-3pp0A: 59.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 734 ALA A 751 LYS A 753 LEU A 796 CYH A 805 THR A 862	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.3A) None 03Q A 1 (-3.3A)	0.92A	5yu9C-3pp0A: 34.8	5yu9C-3pp0A: 59.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxf	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	VAL A 65 ALA A 78 LYS A 80 LEU A 126 ASP A 195	BK5 A 701 (-4.2A) BK5 A 701 (-3.4A) BK5 A 701 (-3.5A) BK5 A 701 (-3.3A) BK5 A 701 (-4.0A)	0.39A	5yu9C-3sxfA: 23.6	5yu9C-3sxfA: 11.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 431 ALA A 443 LYS A 445 GLY A 495 CYH A 496	PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) PP2 A 1 ( 4.2A) None	0.80A	5yu9C-3sxsA: 28.9	5yu9C-3sxsA: 18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 303 ALA A 315 LYS A 317 LEU A 361 GLY A 369 ASP A 434	None	1.03A	5yu9C-3ulzA: 21.2	5yu9C-3ulzA: 15.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 83 ALA A 96 LYS A 98 MET A 144 GLY A 150 ASP A 209	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-3.8A) ANP A 401 ( 4.3A) MG A 402 (-3.2A)	0.76A	5yu9C-3wigA: 23.4	5yu9C-3wigA: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 91 ALA A 104 LYS A 106 LEU A 152 GLY A 160	VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-3.3A) None VX6 A 500 (-3.3A)	0.71A	5yu9C-4af3A: 18.9	5yu9C-4af3A: 12.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 ALA A 233 LYS A 235 LEU A 281 GLY A 289 ASP A 293 ASP A 354	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) None TAK A1507 (-3.5A) None TAK A1507 (-3.5A)	0.88A	5yu9C-4c02A: 24.5	5yu9C-4c02A: 15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	5	VAL A 24 ALA A 37 LYS A 39 LEU A 85 ASP A 151	ANP A 300 ( 4.7A) ANP A 300 ( 3.8A) ANP A 300 (-3.1A) None None	0.75A	5yu9C-4eqmA: 23.0	5yu9C-4eqmA: 14.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 385 ALA A 400 LYS A 402 LEU A 446 GLY A 454 ASP A 512	0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-3.9A)	1.06A	5yu9C-4f4pA: 25.7	5yu9C-4f4pA: 45.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	VAL A 385 ALA A 400 LYS A 402 MET A 424 LEU A 446 GLY A 454 ASP A 512	ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) None None ANP A 701 ( 4.2A) MG A 702 ( 3.1A)	0.55A	5yu9C-4fl3A: 31.3	5yu9C-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 385 ALA A 400 LYS A 402 MET A 448 GLY A 454 ASP A 512	ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 ( 3.7A) ANP A 701 ( 4.2A) MG A 702 ( 3.1A)	0.84A	5yu9C-4fl3A: 31.3	5yu9C-4fl3A: 7.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 863 ALA A 880 LEU A 927 GLY A 935 ASP A 939 ASP A 994	None IZA A2001 (-3.4A) None IZA A2001 (-3.3A) None IZA A2001 ( 4.5A)	1.09A	5yu9C-4gl9A: 21.7	5yu9C-4gl9A: 15.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 836 ALA A 853 LEU A 900 GLY A 908 CYH A 909 ASP A 912	19S A1201 (-4.4A) 19S A1201 (-3.3A) None 19S A1201 ( 3.8A) None None	0.91A	5yu9C-4hviA: 29.4	5yu9C-4hviA: 13.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	VAL A 140 ALA A 156 LYS A 158 MET A 181 GLY A 211 ASP A 215 ASP A 270	None	0.75A	5yu9C-4hzsA: 31.0	5yu9C-4hzsA: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 140 ALA A 156 LYS A 158 GLY A 211 ASP A 215	1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 ( 4.5A) None	0.68A	5yu9C-4id7A: 24.4	5yu9C-4id7A: 15.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 LYS A 295 MET A 314 GLY A 344 ASP A 348 ASP A 404	0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.1A) None 0J9 A 601 (-3.1A)	0.65A	5yu9C-4k11A: 32.1	5yu9C-4k11A: 15.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ks8	SERINE/THREONINE-PRO TEIN KINASE PAK 6 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 421 ALA A 434 GLY A 487 ASP A 491 ASP A 544	None B49 A 701 (-3.2A) B49 A 701 ( 3.7A) B49 A 701 ( 4.3A) B49 A 701 (-4.6A)	0.70A	5yu9C-4ks8A: 23.0	5yu9C-4ks8A: 14.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	5	VAL A 281 ALA A 293 LYS A 295 GLY A 344 ASP A 348	VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 3.2A) None	0.66A	5yu9C-4lggA: 27.7	5yu9C-4lggA: 18.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 LYS A 51 LEU A 93 GLY A 101 ASP A 161	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None None MG A 403 ( 3.1A)	0.83A	5yu9C-4m69A: 26.4	5yu9C-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 LYS A 51 MET A 65 LEU A 93 GLY A 101	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None None None	1.13A	5yu9C-4m69A: 26.4	5yu9C-4m69A: 14.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ow8	SERINE/THREONINE-PRO TEIN KINASE PKNA (Mycobacterium tuberculosis)	PF00069 (Pkinase)	6	VAL A 27 ALA A 40 LYS A 42 LEU A 93 THR A 158 ASP A 159	None	0.82A	5yu9C-4ow8A: 23.6	5yu9C-4ow8A: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rgj	CALCIUM-DEPENDENT PROTEIN KINASE 4 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	VAL A 84 ALA A 97 LYS A 99 LEU A 145 ASP A 215	None	0.37A	5yu9C-4rgjA: 23.1	5yu9C-4rgjA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4uya	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 138 ALA A 149 LEU A 198 GLY A 206 THR A 288	AGS A1438 (-4.4A) AGS A1438 (-3.4A) None None AGS A1438 ( 4.7A)	0.63A	5yu9C-4uyaA: 25.7	5yu9C-4uyaA: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 MET A 449 GLY A 480 CYH A 481 ASP A 539	None	0.82A	5yu9C-4xi2A: 29.9	5yu9C-4xi2A: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	5	VAL A 416 ALA A 428 GLY A 480 CYH A 481 ASP A 539	746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.6A) None 746 A 702 (-3.7A)	0.51A	5yu9C-4y93A: 30.3	5yu9C-4y93A: 10.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 18 ALA A 31 LYS A 33 LEU A 78 ASP A 146	None	0.65A	5yu9C-4yc6A: 23.7	5yu9C-4yc6A: 16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	5	VAL A 34 ALA A 47 LYS A 49 LEU A 94 ASP A 160	None	0.57A	5yu9C-4ynzA: 21.3	5yu9C-4ynzA: 12.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 44 LYS A 46 LEU A 90 GLY A 98 ASP A 165	51W A 401 ( 4.3A) 51W A 401 (-3.4A) GOL A 404 ( 3.1A) None 51W A 401 (-3.7A) GOL A 404 (-3.2A)	1.04A	5yu9C-5ci7A: 21.6	5yu9C-5ci7A: 14.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	5	VAL A 89 ALA A 102 LYS A 104 LEU A 148 ASP A 160	ANP A 401 (-4.0A) ANP A 401 ( 4.0A) ANP A 401 (-3.0A) None None	0.70A	5yu9C-5dbxA: 22.0	5yu9C-5dbxA: 14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	5	VAL A 107 ALA A 120 LYS A 122 LEU A 168 GLY A 176	5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) None 5U5 A 401 (-3.4A)	0.61A	5yu9C-5eykA: 15.7	5yu9C-5eykA: 15.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 928 LYS A 930 MET A 978 ASP A 988 ARG A1027 ASP A1041	5U3 A1200 (-3.5A) None 5U3 A1200 ( 4.0A) None 5U3 A1200 ( 4.5A) 5U3 A1200 ( 4.9A)	1.32A	5yu9C-5f1zA: 28.3	5yu9C-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 928 MET A 978 GLY A 984 ASP A 988 ARG A1027 ASP A1041	5U3 A1200 (-3.5A) 5U3 A1200 ( 4.0A) 5U3 A1200 (-3.2A) None 5U3 A1200 ( 4.5A) 5U3 A1200 ( 4.9A)	1.16A	5yu9C-5f1zA: 28.3	5yu9C-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 911 ALA A 928 GLY A 984 ASP A 988 ARG A1027 ASP A1041	5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-3.2A) None 5U3 A1200 ( 4.5A) 5U3 A1200 ( 4.9A)	1.05A	5yu9C-5f1zA: 28.3	5yu9C-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 911 ALA A 928 LYS A 930 ASP A 988 ARG A1027 ASP A1041	5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None None 5U3 A1200 ( 4.5A) 5U3 A1200 ( 4.9A)	1.21A	5yu9C-5f1zA: 28.3	5yu9C-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 911 LEU A 976 GLY A 984 ASP A 988 ARG A1027 ASP A1041	5U3 A1200 ( 4.4A) None 5U3 A1200 (-3.2A) None 5U3 A1200 ( 4.5A) 5U3 A1200 ( 4.9A)	1.37A	5yu9C-5f1zA: 28.3	5yu9C-5f1zA: 15.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 738 ALA A 756 LYS A 758 LEU A 802 GLY A 810	PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PTR A 809 (-2.4A)	0.55A	5yu9C-5fm2A: 28.3	5yu9C-5fm2A: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ig1	CAMK/CAMK2 PROTEIN KINASE (Salpingoeca rosetta)	PF00069 (Pkinase)	5	VAL A 32 ALA A 45 LEU A 92 GLY A 100 THR A 160	None	0.76A	5yu9C-5ig1A: 22.3	5yu9C-5ig1A: 12.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ig1	CAMK/CAMK2 PROTEIN KINASE (Salpingoeca rosetta)	PF00069 (Pkinase)	5	VAL A 32 ALA A 45 LYS A 47 LEU A 92 THR A 160	None	0.79A	5yu9C-5ig1A: 22.3	5yu9C-5ig1A: 12.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 726 ALA A 743 LEU A 788 MET A 790 GLY A 796 CYH A 797 ASP A 800 THR A 854	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 ( 4.6A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.1A) 6HJ A1101 (-3.9A)	0.49A	5yu9C-5j9zA: 35.2	5yu9C-5j9zA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 726 ALA A 743 LYS A 745 LEU A 788 MET A 790 GLY A 796 CYH A 797 THR A 854	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 ( 4.6A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 (-3.9A)	0.72A	5yu9C-5j9zA: 35.2	5yu9C-5j9zA: 95.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 726 ALA A 743 MET A 790 GLY A 796 CYH A 797 ASP A 800 THR A 854 ASP A 855	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.1A) 6HJ A1101 (-3.9A) 6HJ A1101 (-4.3A)	0.72A	5yu9C-5j9zA: 35.2	5yu9C-5j9zA: 95.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 404 ALA A 417 LEU A 463 GLY A 471 ASP A 475	GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None GUI A 701 (-3.6A) GUI A 701 (-4.1A)	0.53A	5yu9C-5jznA: 21.9	5yu9C-5jznA: 16.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 404 ALA A 417 LYS A 419 LEU A 463 GLY A 471	GUI A 701 (-4.4A) GUI A 701 ( 3.9A) GUI A 701 (-3.1A) None GUI A 701 (-3.6A)	0.73A	5yu9C-5jznA: 21.9	5yu9C-5jznA: 16.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 284 ALA A 297 GLY A 350 ASP A 354 THR A 406	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 ( 3.8A) None IPW A 601 (-3.7A)	0.68A	5yu9C-5kbrA: 21.4	5yu9C-5kbrA: 17.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 49 ALA A 60 LEU A 108 GLY A 116 THR A 173	None STU A 901 (-3.3A) None STU A 901 (-3.5A) STU A 901 (-3.5A)	0.62A	5yu9C-5lohA: 16.9	5yu9C-5lohA: 12.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5m09	SERINE/THREONINE-PRO TEIN KINASE PKNI (Mycobacterium tuberculosis)	PF00069 (Pkinase)	5	VAL A 26 ALA A 39 LYS A 41 MET A 89 ASP A 159	None	0.78A	5yu9C-5m09A: 21.0	5yu9C-5m09A: 13.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	VAL A 899 ALA A 917 LYS A 919 MET A 938 THR A1027 ASP A1028	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) None ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.96A	5yu9C-5wnoA: 34.5	5yu9C-5wnoA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	VAL A 899 ALA A 917 MET A 938 GLY A 969 THR A1027 ASP A1028	ANP A1201 (-4.4A) ANP A1201 (-3.3A) None ANP A1201 ( 4.6A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.81A	5yu9C-5wnoA: 34.5	5yu9C-5wnoA: 42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	5	VAL A 83 LYS A 97 LEU A 139 GLY A 147 ASP A 151	ANP A1000 (-4.1A) ANP A1000 (-2.8A) None None ANP A1000 ( 4.9A)	0.75A	5yu9C-5xd6A: 23.7	5yu9C-5xd6A: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	6	VAL A 212 ALA A 225 GLY A 279 ASP A 283 THR A 338 ASP A 339	None	0.86A	5yu9C-5xzwA: 18.5	5yu9C-5xzwA: 10.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5yks	SNF-RELATED SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	no annotation	6	ALA A 43 LEU A 90 GLY A 98 ASP A 102 THR A 157 ASP A 158	None	0.93A	5yu9C-5yksA: 19.3	5yu9C-5yksA: 12.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	VAL A 41 ALA A 54 LYS A 56 MET A 74 GLY A 105 ASP A 164	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None ANP A 501 ( 4.0A) MG A 502 ( 3.1A)	0.86A	5yu9C-6ao5A: 23.4	5yu9C-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	VAL A 41 ALA A 54 LYS A 56 MET A 99 GLY A 105 ASP A 164	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) ANP A 501 (-2.5A) ANP A 501 ( 4.0A) MG A 502 ( 3.1A)	0.77A	5yu9C-6ao5A: 23.4	5yu9C-6ao5A: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	5	VAL A 226 ALA A 237 LEU A 286 GLY A 294 ASP A 358	None DL1 A 601 (-3.4A) None DL1 A 601 (-3.5A) DL1 A 601 (-3.1A)	0.48A	5yu9C-6bfnA: 22.6	5yu9C-6bfnA: 29.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6eqi	SERINE/THREONINE-PRO TEIN KINASE PINK1, PUTATIVE (Pediculus humanus)	no annotation	5	VAL C 173 ALA C 191 LEU C 288 THR C 356 ASP C 357	None	0.57A	5yu9C-6eqiC: 19.6	5yu9C-6eqiC: 12.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6eqi	SERINE/THREONINE-PRO TEIN KINASE PINK1, PUTATIVE (Pediculus humanus)	no annotation	6	VAL C 173 ALA C 191 LYS C 193 MET C 290 THR C 356 ASP C 357	None	1.22A	5yu9C-6eqiC: 19.6	5yu9C-6eqiC: 12.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	5	VAL A 200 ALA A 211 LEU A 260 GLY A 268 ASP A 272	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) None CJT A 502 ( 4.3A) CJT A 502 (-3.3A)	0.59A	5yu9C-6f3dA: 22.0	5yu9C-6f3dA: 26.14

[["5YU9_C_1E8C1101_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;ASP A 539","None","0.89A","5yu9C-1k2pA:28.4","5yu9C-1k2pA:14.77"],["5YU9_C_1E8C1101_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"VAL A 209;ALA A 220;GLY A 272;ASP A 276;ASP A 332","None","0.71A","5yu9C-1k9aA:29.6","5yu9C-1k9aA:12.83"],["5YU9_C_1E8C1101_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"VAL A 219;ALA A 230;LEU A 278;GLY A 286;ASP A 351","PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.8A);PY1 A 700 (-3.6A);PY1 A 700 (-2.7A)","0.68A","5yu9C-1py5A:24.3","5yu9C-1py5A:11.15"],["5YU9_C_1E8C1101_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 219;ALA A 230;LYS A 232;GLY A 286;ASP A 290;ASP A 351","PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.9A);PY1 A 700 (-3.6A);None;PY1 A 700 (-2.7A)","1.00A","5yu9C-1py5A:24.3","5yu9C-1py5A:11.15"],["5YU9_C_1E8C1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",5,"ALA A  99;LYS A 101;MET A 147;GLY A 153;ASP A 212","ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 3.4A);ATP A 535 ( 4.7A); MG A 536 (-3.3A)","0.74A","5yu9C-1s9iA:16.0","5yu9C-1s9iA:15.71"],["5YU9_C_1E8C1101_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",5,"VAL A  86;ALA A  99;LYS A 101;GLY A 153;ASP A 212","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);ATP A 535 ( 4.7A); MG A 536 (-3.3A)","0.62A","5yu9C-1s9iA:16.0","5yu9C-1s9iA:15.71"],["5YU9_C_1E8C1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;LEU A 433;GLY A 441;ASP A 445;ASP A 500","None","0.93A","5yu9C-1snxA:22.6","5yu9C-1snxA:16.00"],["5YU9_C_1E8C1101_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;LEU A 433;GLY A 441;CYH A 442;ASP A 445","None","0.83A","5yu9C-1snxA:22.6","5yu9C-1snxA:16.00"],["5YU9_C_1E8C1101_1","2b1p","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 10","PF00069(Pkinase)",5,"VAL A  78;ALA A  91;LYS A  93;LEU A 144;MET A 146","AIZ A 501 ( 4.7A);AIZ A 501 (-3.4A);AIZ A 501 (-3.8A);AIZ A 501 (-4.2A);AIZ A 501 (-3.8A)","0.45A","5yu9C-2b1pA:18.0","5yu9C-2b1pA:14.94"],["5YU9_C_1E8C1101_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;ASP A 404","H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;H8H A 534 (-3.3A);None;H8H A 534 (-4.2A)","0.70A","5yu9C-2h8hA:32.1","5yu9C-2h8hA:12.89"],["5YU9_C_1E8C1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;ASP A 404","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.0A);QUE A   1 ( 4.1A);None","0.98A","5yu9C-2hckA:30.2","5yu9C-2hckA:11.29"],["5YU9_C_1E8C1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"VAL A 352;ALA A 367;LYS A 369;MET A 390;LEU A 412;GLY A 420;ASP A 479","ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;None;ANP A 615 ( 3.9A); MG A 614 ( 3.2A)","0.76A","5yu9C-2ozoA:22.7","5yu9C-2ozoA:8.25"],["5YU9_C_1E8C1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 352;ALA A 367;MET A 390;MET A 414;GLY A 420;ASP A 479","ANP A 615 (-4.5A);ANP A 615 (-3.3A);None;ANP A 615 ( 3.9A);ANP A 615 ( 3.9A); MG A 614 ( 3.2A)","1.18A","5yu9C-2ozoA:22.7","5yu9C-2ozoA:8.25"],["5YU9_C_1E8C1101_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 352;LYS A 369;MET A 390;LEU A 412;GLY A 418;ASP A 479","ANP A 615 (-4.5A);ANP A 615 (-3.1A);None;None;ANP A 615 ( 4.0A); MG A 614 ( 3.2A)","1.01A","5yu9C-2ozoA:22.7","5yu9C-2ozoA:8.25"],["5YU9_C_1E8C1101_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"VAL A  33;ALA A  46;LEU A 101;GLY A 109;ASP A 113;THR A 166","ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;None;ATP A 381 ( 4.6A)","0.71A","5yu9C-2phkA:21.6","5yu9C-2phkA:17.20"],["5YU9_C_1E8C1101_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;LYS B  69;LEU B 112;GLY B 120;THR B 181","None","0.72A","5yu9C-2qkwB:21.9","5yu9C-2qkwB:15.38"],["5YU9_C_1E8C1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LEU A 263;GLY A 271;ASP A 275;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 ( 4.1A);None;None","0.82A","5yu9C-2qluA:23.7","5yu9C-2qluA:14.33"],["5YU9_C_1E8C1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LYS A 217;LEU A 263;ASP A 275;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;None;None;None","0.97A","5yu9C-2qluA:23.7","5yu9C-2qluA:14.33"],["5YU9_C_1E8C1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"ALA A 749;LYS A 751;LEU A 794;ARG A 847;THR A 860;ASP A 861","GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);None;GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","1.35A","5yu9C-2r4bA:37.2","5yu9C-2r4bA:18.38"],["5YU9_C_1E8C1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",5,"LYS A 751;MET A 772;LEU A 794;THR A 860;ASP A 861","GW7 A   1 (-3.9A);GW7 A   1 ( 3.8A);GW7 A   1 (-4.1A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.75A","5yu9C-2r4bA:37.2","5yu9C-2r4bA:18.38"],["5YU9_C_1E8C1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"VAL A 732;ALA A 749;LYS A 751;LEU A 794;GLY A 802;THR A 860","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);GW7 A   1 (-3.6A);GW7 A   1 (-3.5A)","0.75A","5yu9C-2r4bA:37.2","5yu9C-2r4bA:18.38"],["5YU9_C_1E8C1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"VAL A 732;ALA A 749;LYS A 751;LEU A 794;THR A 860;ASP A 861","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.65A","5yu9C-2r4bA:37.2","5yu9C-2r4bA:18.38"],["5YU9_C_1E8C1101_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",5,"VAL A 234;ALA A 247;GLY A 307;ASP A 311;THR A 367","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 ( 3.7A);None;XK9 A1511 (-3.7A)","0.48A","5yu9C-2xk9A:11.7","5yu9C-2xk9A:14.85"],["5YU9_C_1E8C1101_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",5,"VAL A 234;ALA A 247;LYS A 249;GLY A 307;ASP A 311","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.2A);XK9 A1511 ( 3.7A);None","0.79A","5yu9C-2xk9A:11.7","5yu9C-2xk9A:14.85"],["5YU9_C_1E8C1101_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",5,"VAL A  38;ALA A  51;GLY A 113;ASP A 117;ASP A 171","None;B49 A1294 (-3.2A);B49 A1294 (-3.6A);None;B49 A1294 (-4.2A)","0.70A","5yu9C-2y7jA:21.9","5yu9C-2y7jA:13.22"],["5YU9_C_1E8C1101_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",5,"VAL A  38;ALA A  51;LEU A 105;GLY A 113;ASP A 117","None;B49 A1294 (-3.2A);None;B49 A1294 (-3.6A);None","0.49A","5yu9C-2y7jA:21.9","5yu9C-2y7jA:13.22"],["5YU9_C_1E8C1101_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",5,"VAL A  76;ALA A  92;LYS A  94;LEU A 139;THR A 204","None;STU A   1 (-3.3A);STU A   1 (-2.8A);None;STU A   1 (-3.6A)","0.69A","5yu9C-2z7rA:21.8","5yu9C-2z7rA:12.77"],["5YU9_C_1E8C1101_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",5,"VAL A 261;ALA A 273;LYS A 275;GLY A 325;ASP A 329","None","0.73A","5yu9C-2zv7A:25.2","5yu9C-2zv7A:18.80"],["5YU9_C_1E8C1101_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",5,"VAL A 209;ALA A 220;GLY A 272;ASP A 276;ASP A 332","None","0.71A","5yu9C-3d7uA:24.2","5yu9C-3d7uA:19.23"],["5YU9_C_1E8C1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",7,"VAL A  31;ALA A  44;LYS A  46;MET A  67;LEU A  90;ASP A 102;ASP A 164","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);ANP A   1 (-2.8A);None;None;None;ANP A   1 (-3.8A)","0.83A","5yu9C-3dakA:22.4","5yu9C-3dakA:15.25"],["5YU9_C_1E8C1101_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"VAL A  31;ALA A  44;MET A  67;LEU A  90;GLY A  98;ASP A 164","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None;None;ANP A   1 (-3.8A)","0.77A","5yu9C-3dakA:22.4","5yu9C-3dakA:15.25"],["5YU9_C_1E8C1101_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",5,"VAL A 158;ALA A 169;LEU A 218;GLY A 226;THR A 293","VIN A6331 (-4.7A);VIN A6331 (-3.4A);None;VIN A6331 (-3.4A);VIN A6331 (-3.6A)","0.48A","5yu9C-3dtcA:19.7","5yu9C-3dtcA:14.45"],["5YU9_C_1E8C1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",5,"VAL A  37;ALA A  50;LEU A  98;ASP A 110;ASP A 167","None","0.57A","5yu9C-3dxnA:24.6","5yu9C-3dxnA:14.98"],["5YU9_C_1E8C1101_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",5,"VAL A  37;ALA A  50;LEU A  98;GLY A 106;ASP A 167","None","0.55A","5yu9C-3dxnA:24.6","5yu9C-3dxnA:14.98"],["5YU9_C_1E8C1101_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",5,"ALA A 247;GLY A 307;ASP A 311;THR A 367;ASP A 368","None","0.69A","5yu9C-3i6uA:22.2","5yu9C-3i6uA:10.83"],["5YU9_C_1E8C1101_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",6,"VAL A 704;LYS A 723;LEU A 766;GLY A 774;ASP A 778;ASP A 833","ANP A   1 (-3.9A);ANP A   1 (-3.4A);None;ANP A   1 ( 4.9A);None; MG A1001 ( 3.1A)","0.70A","5yu9C-3kexA:30.1","5yu9C-3kexA:15.79"],["5YU9_C_1E8C1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",9,"ALA A 719;LYS A 721;MET A 742;LEU A 764;GLY A 772;CYH A 773;ASP A 776;THR A 830;ASP A 831","ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.4A);ITI A   1 ( 4.2A);ITI A   1 (-3.5A);ITI A   1 (-4.8A);None;ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","0.76A","5yu9C-3lzbA:38.9","5yu9C-3lzbA:95.00"],["5YU9_C_1E8C1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 753;GLY A 772;CYH A 773;ASP A 776;THR A 830;ASP A 831","ITI A   1 (-3.8A);ITI A   1 (-3.5A);ITI A   1 (-4.8A);None;ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","1.29A","5yu9C-3lzbA:38.9","5yu9C-3lzbA:95.00"],["5YU9_C_1E8C1101_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",9,"VAL A 702;ALA A 719;LYS A 721;MET A 742;LEU A 764;CYH A 773;ASP A 776;THR A 830;ASP A 831","ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.4A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A);None;ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","0.75A","5yu9C-3lzbA:38.9","5yu9C-3lzbA:95.00"],["5YU9_C_1E8C1101_1","3pls","Homo sapiens","MACROPHAGE-STIMULATING PROTEIN RECEPTOR","PF07714(Pkinase_Tyr)",5,"VAL A1096;ALA A1112;LYS A1114;GLY A1167;ASP A1226","ANP A1358 (-4.4A);ANP A1358 ( 3.8A);ANP A1358 (-3.2A);None; MG A   1 ( 3.2A)","0.65A","5yu9C-3plsA:30.4","5yu9C-3plsA:16.03"],["5YU9_C_1E8C1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"VAL A 734;ALA A 751;LEU A 796;GLY A 804;CYH A 805;ASP A 808;ASP A 863","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);03Q A   1 ( 3.9A);None;None;03Q A   1 (-4.0A)","0.85A","5yu9C-3pp0A:34.8","5yu9C-3pp0A:59.82"],["5YU9_C_1E8C1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"VAL A 734;ALA A 751;LEU A 796;GLY A 804;CYH A 805;ASP A 808;THR A 862","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);03Q A   1 ( 3.9A);None;None;03Q A   1 (-3.3A)","0.62A","5yu9C-3pp0A:34.8","5yu9C-3pp0A:59.82"],["5YU9_C_1E8C1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"VAL A 734;ALA A 751;LYS A 753;LEU A 796;CYH A 805;ASP A 863","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.3A);None;03Q A   1 (-4.0A)","1.11A","5yu9C-3pp0A:34.8","5yu9C-3pp0A:59.82"],["5YU9_C_1E8C1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"VAL A 734;ALA A 751;LYS A 753;LEU A 796;CYH A 805;THR A 862","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.3A);None;03Q A   1 (-3.3A)","0.92A","5yu9C-3pp0A:34.8","5yu9C-3pp0A:59.82"],["5YU9_C_1E8C1101_1","3sxf","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",5,"VAL A  65;ALA A  78;LYS A  80;LEU A 126;ASP A 195","BK5 A 701 (-4.2A);BK5 A 701 (-3.4A);BK5 A 701 (-3.5A);BK5 A 701 (-3.3A);BK5 A 701 (-4.0A)","0.39A","5yu9C-3sxfA:23.6","5yu9C-3sxfA:11.36"],["5YU9_C_1E8C1101_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",5,"VAL A 431;ALA A 443;LYS A 445;GLY A 495;CYH A 496","PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);PP2 A   1 ( 4.2A);None","0.80A","5yu9C-3sxsA:28.9","5yu9C-3sxsA:18.02"],["5YU9_C_1E8C1101_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",6,"VAL A 303;ALA A 315;LYS A 317;LEU A 361;GLY A 369;ASP A 434","None","1.03A","5yu9C-3ulzA:21.2","5yu9C-3ulzA:15.44"],["5YU9_C_1E8C1101_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"VAL A  83;ALA A  96;LYS A  98;MET A 144;GLY A 150;ASP A 209","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-3.8A);ANP A 401 ( 4.3A); MG A 402 (-3.2A)","0.76A","5yu9C-3wigA:23.4","5yu9C-3wigA:16.55"],["5YU9_C_1E8C1101_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",5,"VAL A  91;ALA A 104;LYS A 106;LEU A 152;GLY A 160","VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-3.3A);None;VX6 A 500 (-3.3A)","0.71A","5yu9C-4af3A:18.9","5yu9C-4af3A:12.97"],["5YU9_C_1E8C1101_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;ALA A 233;LYS A 235;LEU A 281;GLY A 289;ASP A 293;ASP A 354","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);None;TAK A1507 (-3.5A);None;TAK A1507 (-3.5A)","0.88A","5yu9C-4c02A:24.5","5yu9C-4c02A:15.41"],["5YU9_C_1E8C1101_1","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A  24;ALA A  37;LYS A  39;LEU A  85;ASP A 151","ANP A 300 ( 4.7A);ANP A 300 ( 3.8A);ANP A 300 (-3.1A);None;None","0.75A","5yu9C-4eqmA:23.0","5yu9C-4eqmA:14.53"],["5YU9_C_1E8C1101_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"VAL A 385;ALA A 400;LYS A 402;LEU A 446;GLY A 454;ASP A 512","0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-3.9A)","1.06A","5yu9C-4f4pA:25.7","5yu9C-4f4pA:45.71"],["5YU9_C_1E8C1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"VAL A 385;ALA A 400;LYS A 402;MET A 424;LEU A 446;GLY A 454;ASP A 512","ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);None;None;ANP A 701 ( 4.2A); MG A 702 ( 3.1A)","0.55A","5yu9C-4fl3A:31.3","5yu9C-4fl3A:7.85"],["5YU9_C_1E8C1101_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 385;ALA A 400;LYS A 402;MET A 448;GLY A 454;ASP A 512","ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 ( 3.7A);ANP A 701 ( 4.2A); MG A 702 ( 3.1A)","0.84A","5yu9C-4fl3A:31.3","5yu9C-4fl3A:7.85"],["5YU9_C_1E8C1101_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL A 863;ALA A 880;LEU A 927;GLY A 935;ASP A 939;ASP A 994","None;IZA A2001 (-3.4A);None;IZA A2001 (-3.3A);None;IZA A2001 ( 4.5A)","1.09A","5yu9C-4gl9A:21.7","5yu9C-4gl9A:15.99"],["5YU9_C_1E8C1101_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"VAL A 836;ALA A 853;LEU A 900;GLY A 908;CYH A 909;ASP A 912","19S A1201 (-4.4A);19S A1201 (-3.3A);None;19S A1201 ( 3.8A);None;None","0.91A","5yu9C-4hviA:29.4","5yu9C-4hviA:13.27"],["5YU9_C_1E8C1101_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"VAL A 140;ALA A 156;LYS A 158;MET A 181;GLY A 211;ASP A 215;ASP A 270","None","0.75A","5yu9C-4hzsA:31.0","5yu9C-4hzsA:13.99"],["5YU9_C_1E8C1101_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",5,"VAL A 140;ALA A 156;LYS A 158;GLY A 211;ASP A 215","1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 ( 4.5A);None","0.68A","5yu9C-4id7A:24.4","5yu9C-4id7A:15.60"],["5YU9_C_1E8C1101_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;LYS A 295;MET A 314;GLY A 344;ASP A 348;ASP A 404","0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.1A);None;0J9 A 601 (-3.1A)","0.65A","5yu9C-4k11A:32.1","5yu9C-4k11A:15.57"],["5YU9_C_1E8C1101_1","4ks8","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 6","PF00069(Pkinase)",5,"VAL A 421;ALA A 434;GLY A 487;ASP A 491;ASP A 544","None;B49 A 701 (-3.2A);B49 A 701 ( 3.7A);B49 A 701 ( 4.3A);B49 A 701 (-4.6A)","0.70A","5yu9C-4ks8A:23.0","5yu9C-4ks8A:14.19"],["5YU9_C_1E8C1101_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",5,"VAL A 281;ALA A 293;LYS A 295;GLY A 344;ASP A 348","VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 3.2A);None","0.66A","5yu9C-4lggA:27.7","5yu9C-4lggA:18.80"],["5YU9_C_1E8C1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;LYS A  51;LEU A  93;GLY A 101;ASP A 161","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;None; MG A 403 ( 3.1A)","0.83A","5yu9C-4m69A:26.4","5yu9C-4m69A:14.43"],["5YU9_C_1E8C1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;LYS A  51;MET A  65;LEU A  93;GLY A 101","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;None;None","1.13A","5yu9C-4m69A:26.4","5yu9C-4m69A:14.43"],["5YU9_C_1E8C1101_1","4ow8","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNA","PF00069(Pkinase)",6,"VAL A  27;ALA A  40;LYS A  42;LEU A  93;THR A 158;ASP A 159","None","0.82A","5yu9C-4ow8A:23.6","5yu9C-4ow8A:15.06"],["5YU9_C_1E8C1101_1","4rgj","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 4","PF00069(Pkinase);PF13499(EF-hand_7)",5,"VAL A  84;ALA A  97;LYS A  99;LEU A 145;ASP A 215","None","0.37A","5yu9C-4rgjA:23.1","5yu9C-4rgjA:10.40"],["5YU9_C_1E8C1101_1","4uya","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4","PF07714(Pkinase_Tyr)",5,"VAL A 138;ALA A 149;LEU A 198;GLY A 206;THR A 288","AGS A1438 (-4.4A);AGS A1438 (-3.4A);None;None;AGS A1438 ( 4.7A)","0.63A","5yu9C-4uyaA:25.7","5yu9C-4uyaA:16.00"],["5YU9_C_1E8C1101_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;MET A 449;GLY A 480;CYH A 481;ASP A 539","None","0.82A","5yu9C-4xi2A:29.9","5yu9C-4xi2A:11.21"],["5YU9_C_1E8C1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",5,"VAL A 416;ALA A 428;GLY A 480;CYH A 481;ASP A 539","746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.6A);None;746 A 702 (-3.7A)","0.51A","5yu9C-4y93A:30.3","5yu9C-4y93A:10.73"],["5YU9_C_1E8C1101_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",5,"VAL A  18;ALA A  31;LYS A  33;LEU A  78;ASP A 146","None","0.65A","5yu9C-4yc6A:23.7","5yu9C-4yc6A:16.67"],["5YU9_C_1E8C1101_1","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",5,"VAL A  34;ALA A  47;LYS A  49;LEU A  94;ASP A 160","None","0.57A","5yu9C-4ynzA:21.3","5yu9C-4ynzA:12.87"],["5YU9_C_1E8C1101_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"VAL A  30;ALA A  44;LYS A  46;LEU A  90;GLY A  98;ASP A 165","51W A 401 ( 4.3A);51W A 401 (-3.4A);GOL A 404 ( 3.1A);None;51W A 401 (-3.7A);GOL A 404 (-3.2A)","1.04A","5yu9C-5ci7A:21.6","5yu9C-5ci7A:14.08"],["5YU9_C_1E8C1101_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A  89;ALA A 102;LYS A 104;LEU A 148;ASP A 160","ANP A 401 (-4.0A);ANP A 401 ( 4.0A);ANP A 401 (-3.0A);None;None","0.70A","5yu9C-5dbxA:22.0","5yu9C-5dbxA:14.55"],["5YU9_C_1E8C1101_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",5,"VAL A 107;ALA A 120;LYS A 122;LEU A 168;GLY A 176","5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);None;5U5 A 401 (-3.4A)","0.61A","5yu9C-5eykA:15.7","5yu9C-5eykA:15.30"],["5YU9_C_1E8C1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"ALA A 928;LYS A 930;MET A 978;ASP A 988;ARG A1027;ASP A1041","5U3 A1200 (-3.5A);None;5U3 A1200 ( 4.0A);None;5U3 A1200 ( 4.5A);5U3 A1200 ( 4.9A)","1.32A","5yu9C-5f1zA:28.3","5yu9C-5f1zA:15.10"],["5YU9_C_1E8C1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"ALA A 928;MET A 978;GLY A 984;ASP A 988;ARG A1027;ASP A1041","5U3 A1200 (-3.5A);5U3 A1200 ( 4.0A);5U3 A1200 (-3.2A);None;5U3 A1200 ( 4.5A);5U3 A1200 ( 4.9A)","1.16A","5yu9C-5f1zA:28.3","5yu9C-5f1zA:15.10"],["5YU9_C_1E8C1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"VAL A 911;ALA A 928;GLY A 984;ASP A 988;ARG A1027;ASP A1041","5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-3.2A);None;5U3 A1200 ( 4.5A);5U3 A1200 ( 4.9A)","1.05A","5yu9C-5f1zA:28.3","5yu9C-5f1zA:15.10"],["5YU9_C_1E8C1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"VAL A 911;ALA A 928;LYS A 930;ASP A 988;ARG A1027;ASP A1041","5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;None;5U3 A1200 ( 4.5A);5U3 A1200 ( 4.9A)","1.21A","5yu9C-5f1zA:28.3","5yu9C-5f1zA:15.10"],["5YU9_C_1E8C1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"VAL A 911;LEU A 976;GLY A 984;ASP A 988;ARG A1027;ASP A1041","5U3 A1200 ( 4.4A);None;5U3 A1200 (-3.2A);None;5U3 A1200 ( 4.5A);5U3 A1200 ( 4.9A)","1.37A","5yu9C-5f1zA:28.3","5yu9C-5f1zA:15.10"],["5YU9_C_1E8C1101_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",5,"VAL A 738;ALA A 756;LYS A 758;LEU A 802;GLY A 810","PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PTR A 809 (-2.4A)","0.55A","5yu9C-5fm2A:28.3","5yu9C-5fm2A:14.29"],["5YU9_C_1E8C1101_1","5ig1","Salpingoeca rosetta","CAMK\/CAMK2 PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A  32;ALA A  45;LEU A  92;GLY A 100;THR A 160","None","0.76A","5yu9C-5ig1A:22.3","5yu9C-5ig1A:12.91"],["5YU9_C_1E8C1101_1","5ig1","Salpingoeca rosetta","CAMK\/CAMK2 PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A  32;ALA A  45;LYS A  47;LEU A  92;THR A 160","None","0.79A","5yu9C-5ig1A:22.3","5yu9C-5ig1A:12.91"],["5YU9_C_1E8C1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"VAL A 726;ALA A 743;LEU A 788;MET A 790;GLY A 796;CYH A 797;ASP A 800;THR A 854","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 ( 4.6A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.1A);6HJ A1101 (-3.9A)","0.49A","5yu9C-5j9zA:35.2","5yu9C-5j9zA:95.00"],["5YU9_C_1E8C1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"VAL A 726;ALA A 743;LYS A 745;LEU A 788;MET A 790;GLY A 796;CYH A 797;THR A 854","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 ( 4.6A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 (-3.9A)","0.72A","5yu9C-5j9zA:35.2","5yu9C-5j9zA:95.00"],["5YU9_C_1E8C1101_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"VAL A 726;ALA A 743;MET A 790;GLY A 796;CYH A 797;ASP A 800;THR A 854;ASP A 855","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.1A);6HJ A1101 (-3.9A);6HJ A1101 (-4.3A)","0.72A","5yu9C-5j9zA:35.2","5yu9C-5j9zA:95.00"],["5YU9_C_1E8C1101_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",5,"VAL A 404;ALA A 417;LEU A 463;GLY A 471;ASP A 475","GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;GUI A 701 (-3.6A);GUI A 701 (-4.1A)","0.53A","5yu9C-5jznA:21.9","5yu9C-5jznA:16.13"],["5YU9_C_1E8C1101_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",5,"VAL A 404;ALA A 417;LYS A 419;LEU A 463;GLY A 471","GUI A 701 (-4.4A);GUI A 701 ( 3.9A);GUI A 701 (-3.1A);None;GUI A 701 (-3.6A)","0.73A","5yu9C-5jznA:21.9","5yu9C-5jznA:16.13"],["5YU9_C_1E8C1101_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",5,"VAL A 284;ALA A 297;GLY A 350;ASP A 354;THR A 406","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 ( 3.8A);None;IPW A 601 (-3.7A)","0.68A","5yu9C-5kbrA:21.4","5yu9C-5kbrA:17.15"],["5YU9_C_1E8C1101_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",5,"VAL A  49;ALA A  60;LEU A 108;GLY A 116;THR A 173","None;STU A 901 (-3.3A);None;STU A 901 (-3.5A);STU A 901 (-3.5A)","0.62A","5yu9C-5lohA:16.9","5yu9C-5lohA:12.72"],["5YU9_C_1E8C1101_1","5m09","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNI","PF00069(Pkinase)",5,"VAL A  26;ALA A  39;LYS A  41;MET A  89;ASP A 159","None","0.78A","5yu9C-5m09A:21.0","5yu9C-5m09A:13.28"],["5YU9_C_1E8C1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"VAL A 899;ALA A 917;LYS A 919;MET A 938;THR A1027;ASP A1028","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);None;ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.96A","5yu9C-5wnoA:34.5","5yu9C-5wnoA:42.68"],["5YU9_C_1E8C1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"VAL A 899;ALA A 917;MET A 938;GLY A 969;THR A1027;ASP A1028","ANP A1201 (-4.4A);ANP A1201 (-3.3A);None;ANP A1201 ( 4.6A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.81A","5yu9C-5wnoA:34.5","5yu9C-5wnoA:42.68"],["5YU9_C_1E8C1101_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",5,"VAL A  83;LYS A  97;LEU A 139;GLY A 147;ASP A 151","ANP A1000 (-4.1A);ANP A1000 (-2.8A);None;None;ANP A1000 ( 4.9A)","0.75A","5yu9C-5xd6A:23.7","5yu9C-5xd6A:29.21"],["5YU9_C_1E8C1101_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",6,"VAL A 212;ALA A 225;GLY A 279;ASP A 283;THR A 338;ASP A 339","None","0.86A","5yu9C-5xzwA:18.5","5yu9C-5xzwA:10.40"],["5YU9_C_1E8C1101_1","5yks","Homo sapiens","SNF-RELATED SERINE\/THREONINE-PROTEIN KINASE","no annotation",6,"ALA A  43;LEU A  90;GLY A  98;ASP A 102;THR A 157;ASP A 158","None","0.93A","5yu9C-5yksA:19.3","5yu9C-5yksA:12.27"],["5YU9_C_1E8C1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"VAL A  41;ALA A  54;LYS A  56;MET A  74;GLY A 105;ASP A 164","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.0A); MG A 502 ( 3.1A)","0.86A","5yu9C-6ao5A:23.4","5yu9C-6ao5A:13.95"],["5YU9_C_1E8C1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"VAL A  41;ALA A  54;LYS A  56;MET A  99;GLY A 105;ASP A 164","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);ANP A 501 (-2.5A);ANP A 501 ( 4.0A); MG A 502 ( 3.1A)","0.77A","5yu9C-6ao5A:23.4","5yu9C-6ao5A:13.95"],["5YU9_C_1E8C1101_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",5,"VAL A 226;ALA A 237;LEU A 286;GLY A 294;ASP A 358","None;DL1 A 601 (-3.4A);None;DL1 A 601 (-3.5A);DL1 A 601 (-3.1A)","0.48A","5yu9C-6bfnA:22.6","5yu9C-6bfnA:29.07"],["5YU9_C_1E8C1101_1","6eqi","Pediculus humanus","SERINE\/THREONINE-PROTEIN KINASE PINK1, PUTATIVE","no annotation",5,"VAL C 173;ALA C 191;LEU C 288;THR C 356;ASP C 357","None","0.57A","5yu9C-6eqiC:19.6","5yu9C-6eqiC:12.56"],["5YU9_C_1E8C1101_1","6eqi","Pediculus humanus","SERINE\/THREONINE-PROTEIN KINASE PINK1, PUTATIVE","no annotation",6,"VAL C 173;ALA C 191;LYS C 193;MET C 290;THR C 356;ASP C 357","None","1.22A","5yu9C-6eqiC:19.6","5yu9C-6eqiC:12.56"],["5YU9_C_1E8C1101_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",5,"VAL A 200;ALA A 211;LEU A 260;GLY A 268;ASP A 272","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);None;CJT A 502 ( 4.3A);CJT A 502 (-3.3A)","0.59A","5yu9C-6f3dA:22.0","5yu9C-6f3dA:26.14"]]